Overhaul of EU health systems good opportunity for outcomes data providers, says Quintiles

By Natalie Morrison

- Last updated on GMT

Value based drugs pricing: Market gap for outsource firms, Quintiles

Related tags Quintiles

Negotiating funding for drugs with local health authorities prior to commercialisation is the key to success for biopharmas working in the changing European market, says Quintiles.

The firm recently launched a briefing paper, which looks at market access strategies and how they can help biopharmaceutical firms dodge the risks creating by the fragmented industry across the continent.

Quintiles published the report in the wake of discussions in all over Europe about value-based pricing for drugs - where the medicine is priced based on its need in the local area.

Speaking to Outsourcing-Pharma.com, the paper’s author Gareth Williams - UK market access director – said the key thing to consider in the face of the changes is collecting outcomes data to “understand the fabric of local health authorities”,​ and what is important to them.

And for many firms, the easiest way to work closely with the local authorities in the “fragmented” ​European healthcare systems is outsourcing.

However, he told us that not all firms will outsource, and that service providers will probably see the biggest influx from biopharma’s with less consistent pipelines. In other words, not from Big Pharma which is likely to have staff on the ground.

“I think the biggest predictor of whether a company will outsource is depending on their pipeline coming through,”​ he said. “It’s quite an expensive resource to have if you don’t have a consistent pipeline of those products coming through once every 12 months.”

The cost of success

Of added costs to working with providers who specialise in the individual markets and systems, Williams said biopharmas need not worry.

He said: “If the reason you’re collecting outcomes data is to help inform subsequent years’ budget then you could displace how you currently promote the medicine and use the budget set aside for that for outcomes data instead.

"As Europe moves to wards value based pricing I think that is more and more important."

Related news

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us

Webinars

Headlines